giant congenital melanocytic nevi: an update and emerging therapies

Clicks: 131
ID: 130377
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #29 of 35 articles by views in the american journal of the medical sciences

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Giant congenital melanocytic nevi (GCMN) are a rare occurrence. Gain-of-function mutation in the NRAS gene is found to be associated with GCMN, causing abnormal proliferation of embryonic melanoblasts. The two major complications associated with GCMN are malignant melanoma and neurocutaneous melanosis. Treatment of GCMN has conventionally been surgical. However, the role of NRAS inhibitors and inactivation of nevus tissue by high hydrostatic pressure are being explored. We present a case of a 1-day-old neonate born with GCMN, along with a review of the literature.
Reference Key
meshram2018casegiant Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Girish Gulab Meshram;Neeraj Kaur;Kanwaljeet Singh Hura
Journal the american journal of the medical sciences
Year 2018
DOI
10.1159/000487002
URL
https://www.karger.com/Article/FullText/487002
Keywords
neurocutaneous melanosis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.